Inmune Bio ( (INMB) ) has released its Q2 earnings. Here is a breakdown of the information Inmune Bio presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to combat various diseases, with a primary focus on Alzheimer’s, cancer, and inflammatory conditions.
In its latest earnings report for the second quarter of 2025, INmune Bio Inc. shared significant developments across its product platforms, including the DN-TNF platform, CORDStrom, and INKmune. The company also announced key management changes and a successful $19 million direct offering.
The DN-TNF platform’s XPro™ showed promising results in a subset of Alzheimer’s patients, despite missing primary cognitive endpoints in the broader trial. The CORDStrom platform received favorable patent opinions and is advancing towards large-scale manufacturing, while the INKmune™ platform demonstrated positive early results in its phase II trial for prostate cancer. Financially, the company reported a net loss of $24.5 million for the quarter, attributed mainly to a $16.5 million impairment charge, but maintained a solid cash position of $33.4 million.
Looking ahead, INmune Bio remains focused on advancing its clinical trials and regulatory submissions, with plans to file a Marketing Authorization Application in the UK and a Biologic License Application for CORDStrom by mid-2026. The company aims to expand its pipeline and pursue additional indications through partnerships and non-dilutive funding.